´ëÀå¾Ï

HOME>¿¬±¸È¸ > ¿¬±¸È¸ °Ô½ÃÆÇ

´ëÀå¾Ï


1. ¿ªÇÐ
    • ÃÖ±Ù ½Ä½À°üÀÇ º¯È­, ¼­±¸È­µÈ »ýÈ°½À°ü µîÀ¸·Î ÀÎÇÏ¿© ´ëÀå¾Ï ¹ß»ý·üÀÌ ºü¸£°Ô Áõ°¡ÇÏ°í ÀÖ´Ù. º¸°Çº¹ÁöºÎ Á߾Ӿϵî·Ïº»ºÎ¿¡ µû¸£¸é ¸Å³â ¾à 20¸¸°Ç ÀÌ»óÀÇ ½Å±Ô ¾ÏȯÀÚ°¡ ¹ß»ýÇÏ´Â °ÍÀ¸·Î ÃßÁ¤µÇ°í ÀÖ´Ù. ¾ÏÁ¾º°·Î º¸¸é ³²ÀÚÀÇ °æ¿ì, À§¾Ï, ´ëÀå¾Ï, Æó¾Ï, °£¾Ï ¼øÀ¸·Î ¾Ï ¹ß»ýÀÌ ¸¹¾ÒÀ¸¸ç, ¿©ÀÚÀÇ °æ¿ì, °©»ó¼±¾Ï, À¯¹æ¾Ï, ´ëÀå¾Ï, À§¾Ï, Æó¾Ï ¼øÀ¸·Î ¾Ï ¹ß»ýÀÌ ¸¹¾Ò´Ù. ±×¸®°í, ´ëÀå¾ÏÀÇ 2013³â ¿¬·ÉÇ¥ÁØÈ­ »ç¸Á·üÀº Àα¸ 10¸¸ ¸í´ç ³²ÀÚ 16.1¸í, ¿©ÀÚ 8.5¸íÀ¸·Î »ç¸Á ¼øÀ§´Â ³²ÀÚ 4À§,¿©ÀÚ 2À§¸¦ Â÷ÁöÇÏ¿´´Ù. ´õ¿íÀÌ ´ëÀå¾Ï ¹ß»ý·ü ¹× »ç¸Á·üÀÇ ¿¬µµº° ÃßÀ̸¦ »ìÆ캸¸é, ³²³à ¸ðµÎ¿¡¼­ ´ëÀå¾Ï ¹ß»ý°ú »ç¸ÁÀÌ ¸ðµÎ Áõ°¡ÇÏ´Â Ãß¼¼¸¦ º¸ÀÌ°í ÀÖ´Ù.

2. ¹ßº´ ¿øÀÎ ¹× ±âÀü
    • ºÓÀº À°·ù ¶Ç´Â À°°¡°øÇ° ¼·Ãë´Â ´ëÀå¾ÏÀ» À¯¹ß½ÃÅ°´Â ÁÖ¿ä À§Çè ¿äÀÎÀ¸·Î, ºÓÀº À°·ù ¼·Ãë·® Áõ°¡´Â ÇðöÀÇ ¼·Ãë·® Áõ°¡¸¦ À¯µµÇÏ¿© ´ëº¯ Áß¿¡ ¹ß¾Ï¹°Áú·Î ¾Ë·ÁÁø ATNC(Apparent total N-nitroso compounds) ¹è¼³·® Áõ°¡¸¦ À¯µµÇÏ°Ô µÊ¿¡ µû¶ó ´ëÀå¾ÏÀÇ À§Çèµµ¸¦ ³ôÀÌ´Â °ÍÀ¸·Î ¾Ë·ÁÁ® ÀÖ´Ù. ¶ÇÇÑ ¾ËÄÚ¿Ã ¼·ÃëÀÇ Áõ°¡¿Í ºñ¸¸, À¯ÀüÀûÀÎ ¿äÀÎÀÌ À§ÇèÀÎÀÚ·Î ÀÛ¿ëÇÏ°í ÀÖ´Ù. ƯÈ÷ ºñ¸¸Àº º¹ºÎ ºñ¸¸ÀÎ °æ¿ì¿¡ ´ëÀå¾ÏÀ» À¯¹ß½ÃÅ°´Â °ÍÀ¸·Î º¸°íÇÏ°í ÀÖ´Ù. ÃÖ±ÙÀÇ ¿¬±¸¿¡ ÀÇÇÏ¸é ºñ¸¸ÀÎ °æ¿ì ´ëÀå¾Ï ¹ß»ý À§ÇèÀÌ ¾à 1.5~2.5¹è Á¤µµ Áõ°¡ÇÑ´Ù°í ¾Ë·ÁÁ® ÀÖ´Ù. ÇÑÆí °¡Á·ÀÇ À¯ÀüÀû ¼ÒÀÎÀ¸·Î ÀÎÇÑ ´ëÀå¾Ï ¹ß»ýÀº Àüü ´ëÀå¾Ï ¹ß»ýÀÇ 5~10%·Î, ´ëÀå¾Ï ¹ßº´ À§ÇèÀ» ³ôÀÌ´Â °¡Á·³» À¯Àü Áúȯ¿¡´Â °¡Á·¼º ¿ëÁ¾Áõ(Familial Adenomatous Polyposis; FAP)°ú À¯Àü¼º ºñ¿ëÁ¾Áõ ´ëÀå¾Ï (Hereditary Non-Polyposis Colorectal Cancer; HNPCC)ÀÌ ÀÖ´Ù. FAP°¡ ÀÖ´Â °æ¿ì »ó´ëÀûÀ¸·Î ÀþÀ» ¶§ ¼±Á¾ÀÌ ¹ß»ýÇÏ°í, À̸¦ Ä¡·áÇÏÁö ¾ÊÀ¸¸é °ÅÀÇ ¸ðµç °æ¿ì 40´ë¿¡ À̸£·¯¼­ ´ëÀå¾ÏÀ¸·Î ¹ßÀüÇÏ°Ô µÈ´Ù.

3. ÀÓ»ó Áõ»ó
    • ´ëÀå¾ÏÀÇ ÁÖÁõ»óÀº ´Ù¾çÇÏ°í ºñƯÀÌÀûÀ̸ç ÀϹÝÀûÀ¸·Î º´º¯ÀÇ À§Ä¡¿¡ µû¶ó ¿ìÃø ´ëÀå¾Ï°ú ÁÂÃø ´ëÀå¾ÏÀ¸·Î ³ª´©°í ±× Áõ»óÀÌ À§Ä¡¿¡ µû¶ó Â÷ÀÌ°¡ ÀÖ´Ù. ¿ìÃø ´ëÀå¾ÏÀº ÁÖ·Î Èæ»ö º¯, ºóÇ÷°ú °ü·ÃµÈ ÇÇ·ÎÁõ»óÀ» È£¼ÒÇÏ°í ÁÂÃø ´ëÀå¾ÏÀº ÀåÀÇ ³»°æÀÌ Á¼¾ÆÁ®¼­ ÁÖ·Î Áõ»óÀÌ ¹ß»ýÇÏ¿© º¯ºñ µîÀÇ ¹èº¯½À°üÀÇ º¯È­¸¦ È£¼ÒÇÑ´Ù. º¹ÅëÀÌ ÁÖÁõ»óÀÎ °æ¿ì º¹Åë¿¡ ´ëÇÑ º¹ºÎÀå±â Àü¹ÝÀÇ È®ÀÎÀ» À§ÇØ º¹ºÎ Àü»êÈ­´ÜÃþÃÔ¿µÀ» Ãʱ⿡ ½ÃÇàÇÏ´Â °æÇâÀ» º¸À̴µ¥ ÁÂÃø ´ëÀå¾Ï¿¡¼­µµ º¹ÅëÀº ÈçÇÑ Áõ»óÀÌ´Ù. º¹ÅëÀ̶ó´Â Áõ»óÀº ´Ù¼Ò ¸ðÈ£ÇÏÁö¸¸ ÅëÁõÀÇ Æ¯¼º°ú ¿¬°üÁõ»óÀ» ÆľÇÇÏ°í ÇÊ¿äÇÏ¸é ´ëÀå³»½Ã°æ °Ë»ç¸¦ Á¶±â¿¡ ½ÃÇàÇÏ´Â °ÍÀÌ Áß¿äÇÏ´Ù.

4. Áø´Ü ¹× ¼±º° °Ë»ç
    • ´ëÀå¾ÏÀÇ ¹ß»ý·üÀ» ¿¬·É¿¡ µû¶ó ¾Ë¾Æº¸¸é 50¼¼ ÀÌÀü¿¡´Â ³·´Ù°¡ 50¼¼ ÀüÈĺÎÅÍ ±Þ°ÝÇÏ°Ô ¹ß»ý·üÀÌ Áõ°¡Çϸç ÀÌ´Â ±¹³»¿Ü¿¡¼­ °øÅëÀûÀÎ »ç½ÇÀÌ¸ç µû¶ó¼­ 50¼¼ÀüÈÄ¿¡ ´ëÀå¾Ï¿¡ ´ëÇÑ ¼±º°°Ë»ç¸¦ ½ÃÇàÇÏ´Â °ÍÀº »ó´çÇÑ À¯ÀǼºÀÌ ÀÖ´Ù. ÇÏÁö¸¸, ´ëÀå¾ÏÀÇ ¾à 75%´Â À§ÇèÀÎÀÚ¸¦ °¡Áö°í ÀÖÁö ¾ÊÀº Æò±ÕÀ§ÇèµµÀÇ ÀϹÝÀο¡¼­ ¹ß»ýÇϸç, 25%´Â À§Çèµµ°¡ ³ôÀº °íÀ§Ç豺¿¡¼­ ¹ß»ýÇϹǷΠ¼±º°°Ë»ç¸¦ À§Çؼ­´Â ´ëÀå¾Ï¹ß»ýÀÇ Æò±ÕÀ§Ç豺°ú °íÀ§Ç豺À¸·Î ³ª´©¾î °Ë»ç¸¦ ÁøÇàÇØ¾ß ÇÏ¸ç °¢°¢ÀÇ °æ¿ì¿¡ µû¶ó ¹æ¹ý°ú ½Ã±â¸¦ ´Þ¸® °áÁ¤ÇØ¾ß ÇÑ´Ù.

      ÇöÀç ´ëÀå¾ÏÀÇ ¼±º°°Ë»ç·Î »ç¿ëµÇ°í ÀÖ´Â °Íµé·Î´Â ´ëº¯³» ÀáÇ÷¹ÝÀÀ °Ë»ç, SÀÚ °áÀå ³»½Ã°æ°Ë»ç, ´ëÀå³»½Ã°æ°Ë»ç, ´ëÀåÁ¶¿µ¼ú µîÀÌ ÀÖ´Ù. ¿©·¯ °¡Áö ¼±º°°Ë»ç Áß ´ëº¯³» ÀáÇ÷¹ÝÀÀ °Ë»ç¸¸ÀÌ ¹«ÀÛÀ§ ´ëÁ¶ ¿¬±¸·Î ÀÔÁõµÇ¾úÀ¸³ª ÇöÀç "gold standard"·Î ¿©°ÜÁö´Â °ÍÀº ´ëÀå³»½Ã°æ °Ë»çÀÌ´Ù.


    • 1) ´ëº¯³» ÀáÇ÷¹ÝÀÀ °Ë»ç

      Ç÷»ö¼Ò³» peroxidase À¯»ç È°¼ºÀ» ÀÌ¿ëÇÑ guaiac °Ë»ç¹æ¹ýÀÎ Hemoccult II °Ë»ç°¡ °ªÀÌ Àú·ÅÇÏ°í °£ÆíÇÏ¿© ³Î¸® »ç¿ëÇÏ°í ÀÖ´Ù. ¶ÇÇÑ ºñħ½ÀÀûÀÌ¸ç ´ëÀå¾ÏÀÇ ¹ß»ý·üÀ» ÁÙÀÌ´Â ¹Ì¾àÇÑ È¿°ú°¡ ÀÖÀ¸¸ç »ç¸Á·ü °¨¼Ò¿¡µµ È¿°ú°¡ ÀÖÁö¸¸, ³ôÀº À§¾ç¼º·ü°ú ³·Àº ¿¹¹Îµµ¸¦ º¸ÀδÙ. ÃâÇ÷ÀÌ ÀÖ´Â »ó´çÈ÷ ÁøÇàµÈ ´ëÀå¾Ï¿¡¼­¸¸ ¾ç¼º¹ÝÀÀÀ» º¸À̱⠶§¹®¿¡ »ýÁ¸À²ÀÇ ¸¸Á·½º·± Çâ»óÀ» ±â´ëÇϱ⠾î·Æ°í ¾ç¼º¹ÝÀÀÀÌ ³ªÅ¸³ª¸é ¹Ýµå½Ã ´ëÀå³»½Ã°æÀ» ½ÃÇàÇØ¾ß ÇÑ´Ù. À§¾ç¼º·üµµ ³ô¾Æ¼­ ÇÑ ¹«ÀÛÀ§ ´ëÁ¶¿¬±¸¿¡¼­´Â ´ëº¯³» ÀáÇ÷¹ÝÀÀ °Ë»ç¿¡¼­ ¾ç¼ºÀ» º¸ÀÎ 80%°¡ Ä¡ÇÙÀ̳ª °Ô½ÇÁúȯ µîÀÇ ´Ù¸¥ À§Àå°ü ÁúȯÀÌ ¿øÀÎÀ̾ú´Ù°í º¸°íÇÏ°í ÀÖ´Ù. ÃÖ±Ù¿¡´Â Ç¥ÁØ guaiac °Ë»ç¸¦ ´ëüÇÒ »õ·Î¿î ´ëº¯ ¸é¿ªÈ­Çа˻ç kit°¡ °³¹ßµÇ¾î ¹Ì±¹ FDAÀÇ ½ÂÀÎÀ» ¹Þ¾Ò´Âµ¥, Æò±ÕÀ§Çèµµ¿¡¼­´Â °¨¼ö¼ºÀÌ ´õ ³ô°í ƯÀ̵µ´Â °°À¸³ª °íÀ§Ç豺¿¡¼­´Â °¨¼ö¼ºÀÌ ´õ ³·´Ù´Â º¸°íµµ ÀÖÀ¸¸ç. ¾ÆÁ÷±îÁö ´ëÀå¾Ï »ç¸Á·üÀ» ³·Ãá´Ù´Â ¹«ÀÛÀ§ ºñ±³¿¬±¸´Â ¾ø´Ù. ÀÌ·± ¿©·¯ °¡Áö ¹®Á¦Á¡ ¶§¹®¿¡ ºñ¿ë ´ëºñ È¿°úÀûÀ̶ó´Â º¸°íµµ ÀÖÀ¸³ª ¼±º°°Ë»ç·Î¼­´Â Àç°íÇÒ ¸¸ÇÑ ¿©Áö°¡ ¸¹´Ù.


    • 2) SÀÚ °áÀå ³»½Ã°æ°Ë»ç

      ´ëÀå³»½Ã°æ¿¡ ºñÇØ ¿ÏÀüÇÏÁö´Â ¾ÊÀ¸³ª ½ÃÇàÀÌ ¿ëÀÌÇÏ¸ç ¾ÈÀüÇÏ°í ºñ¿ë ´ëºñ È¿°úÀûÀ̶ó´Â º¸°í°¡ ÀÖ¾î21 ¿©·¯ Àü¹®´Üü¿¡¼­ ¸Å 5³â ÁÖ±â·Î ±Ç°íÇÏ°í ÀÖ°í ´ëÀå¾ÏÀ¸·Î ÀÎÇÑ ¿øÀ§ºÎ ´ëÀå¾ÏÀÇ ¹ß»ý·ü°ú »ç¸Á·üÀ» ÁÙÀÌ´Â °ÍÀ¸·Î ¾Ë·ÁÁ® ÀÖÀ¸³ª ¼±Á¾ÀÌ ¹ß°ßµÉ °æ¿ì Àü´ëÀå ³»½Ã°æÀ» ½ÃÇàÇØ¾ß ÇÏ°í ´ëÀå³»½Ã°æ°ú À¯»çÇÑ ÀåÁ¤°áÀÌ ÇÊ¿äÇϹǷΠ±× ÀÌ¿ë¿¡ Á¦ÇÑÀÌ ÀÖ´Ù. SÀÚ °áÀå ³»½Ã°æ°Ë»ç¿¡¼­ ¿ëÁ¾ÀÌ ¹ß°ßµÈ ÈÄ ´ëÀå³»½Ã°æÀ» ½ÃÇàÇÑ °æ¿ì ´ëÀå¾ÏÀÇ ¹ß»ý·üÀ» 80% °¨¼Ò½ÃÄ×´Ù´Â ¹«ÀÛÀ§ ´ëÁ¶¿¬±¸µµ ÀÖ´Ù. ±×·¯³ª SÀÚ °áÀå°æ ¼±º°°Ë»ç¿¡ ÀÇÇÑ ´ëÀå¾ÏÀÇ »ç¸Á·ü ¹× ºóµµÀÇ °¨¼Ò, Áï È¿À²¼ºÀº ¾ÆÁ÷ ¹«ÀÛÀ§ ´ëÁ¶¿¬±¸¿¡ ÀÇÇØ Æò°¡ÇÏÁö ¸øÇÏ°í ÀÖ´Ù.


    • 3) ´ëÀåÁ¶¿µ¼ú (ÀÌÁßÁ¶¿µ ¹Ù·ý°üÀå°Ë»ç)

      5 mm ÀÌÇÏÀÇ ¿ëÁ¾ÀÇ ¿¹¹Îµµ´Â 35¡­50%·Î ³·À¸¸ç 5¡­7 mm Å©±âÀÇ ¿ëÁ¾ÀÇ ¿¹¹Îµµ´Â 70% Á¤µµÀÌ°í, 1 cm ÀÌ»óÀÇ ¿ëÁ¾À̳ª ´ëÀå¾Ï¿¡ ´ëÇÑ ¿¹¹Îµµ´Â 75¡­90%, ƯÀ̵µ´Â 90% ÀÌ»óÀ¸·Î º¸°íÇÏ°í ÀÖ°í 18%ÀÇ ³ôÀº À§¾ç¼º·üÀ» º¸ÀδÙ. ¶ÇÇÑ ¿ëÁ¾À» ¹ß°ß ½Ã Á¶Á÷°Ë»ç³ª Á¦°Å¸¦ À§ÇØ ´ëÀå³»½Ã°æÀ» Ãß°¡·Î ½ÃÇàÇØ¾ß ÇÑ´Ù´Â ´ÜÁ¡ÀÌ ÀÖ´Ù. ¾ÆÁ÷±îÁö ´ëÀåÁ¶¿µ¼ú ¼±º°°Ë»ç°¡ ´ëÀå¾ÏÀÇ ¹ß»ý·üÀ̳ª »ç¸Á·üÀ» ³·Ãá´Ù´Â ¹«ÀÛÀ§ ´ëÁ¶¿¬±¸´Â ¾ø´Ù. ´ëÀåÁ¶¿µ¼ú¿¡ SÀÚ °áÀå ³»½Ã°æ°Ë»ç¸¦ Ãß°¡ÇÏ´Â °ÍÀº ¼±º°°Ë»ç¿¡¼­ ±Ç°íµÇÁö ¾Ê´Âµ¥ ¹ß°ßÀ² Áõ°¡´Â ºÒÈ®½ÇÇϸ鼭µµ ºñ¿ëÁõ°¡¿Í ºÒÆíÇÔÀÇ ¹®Á¦°¡ ¹ß»ýÇϱ⠶§¹®ÀÌ´Ù.


    • 4) ´ëÀå³»½Ã°æ

      µÎ°³ÀÇ ´ë±Ô¸ð ÀüÇâ ¿¬±¸¿¡¼­ ÁøÇ༺ ±ÙÀ§ºÎ Á¾¾çÀÇ ¾à 50%¿¡¼­ ¿øÀ§ºÎ ´ëÀå¿ëÁ¾ÀÌ ¾ø¾ú°í, ±ÙÀ§ºÎ ´ëÀå¾ÏÀ» °¡Áø Æò±ÕÀ§Ç豺¿¡ ´ëÇÑ ÀüÇ⿬±¸¿¡¼­´Â ´ë»ó±ºÀÇ 65%¿¡¼­ ¿øÀ§ºÎ ´ëÀå¿ëÁ¾ÀÌ ¾ø¾ú´Ù. ÀÌ·± »óȲ¿¡¼­´Â SÀÚ °áÀå ³»½Ã°æ°Ë»ç¸¸À¸·Î ´ëÀå¾Ï ¼±º°°Ë»ç·Î ½ÃÇàÇÏ´Â °ÍÀº ¹«¸®°¡ ÀÖ´Ù. ÀÌ·ÐÀûÀ¸·Î ´ëÀå¾ÏÀÇ ¼±º°°Ë»ç·Î °¡Àå ¿ì¼öÇÒ °ÍÀ¸·Î º¸ÀÌ´Â °Ë»ç´Â ´ëÀå³»½Ã°æ °Ë»çÀ̳ª ¾ÆÁ÷ È¿¿ë¼º¿¡ À־´Â ¹«ÀÛÀ§ ÀÓ»ó½ÇÇè¿¡ ÀÇÇØ Æò°¡µÈ ÀûÀº¾ø´Ù. ´ÜÁö SÀÚ °áÀå°æ ´Üµ¶ ¶Ç´Â SÀÚ °áÀå°æ°ú ´ëº¯ÀáÇ÷°Ë»ç¸¦ º´ÇàÇßÀ» ¶§º¸´Ù ¿¹¹ÎÇÑ °Ë»çÀÌ¸ç ºñ¿ëÈ¿°ú Ãø¸é¿¡¼­ ´õ ³ôÀº È¿À²·Î ´ëÀå¾ÏÀ¸·Î ÀÎÇÑ »ç¸Á·üÀ» ³·Ãá´Ù´Â ÀÏ·ÃÀÇ Áõ·Ê-´ëÁ¶¿¬±¸°á°ú³ª ¼öÇÐÀûÀÎ ¸ðµ¨¸µ¿¡¼­ ¾ò¾îÁø °£Á¢ÀûÀÎ Áõ°Åµé¿¡ ±Ù°ÅÇÏ¿© ÃßõµÇ°í ÀÖ´Ù. ¿ì¸®³ª¶ó¿¡¼­µµ ¼±º°°Ë»ç·Î ´ëÀå³»½Ã°æ °Ë»ç¸¦ ÃßõÇÏ°í ÀÖ´Ù.

5. º´±âÀÇ ¼³Á¤
    • ´ëÀå¾ÏÀÇ º´±â¸¦ Á¤ÇÏ´Â ¹æ¹ý¿¡´Â ¿©·¯ °¡Áö°¡ ÀÖÀ¸¸ç ÀϹÝÀûÀ¸·Î 1930³â¿¡ ¹ßÇ¥µÈ µàÅ©½ºº´±â¸¦ ¾Æ½ºÆ²·¯¿Í ÄÝ·¯°¡ º¯ÇüÇÑ º¯ÇüµÈ µàÅ©½ºº´±â¸¦ ¸¹ÀÌ ¾¹´Ï´Ù. ¾Ï¼¼Æ÷°¡ ħ¹üÇÑ À庮ÀÇ ±íÀÌ¿Í ¸²ÇÁÀý ÀüÀ̸¦ °í·ÁÇÏ¿© A, B, C·Î ³ª´©¸ç ¿ø°ÝÀüÀÌ°¡ ÀÖ´Â °æ¿ì´Â D ·Î ±¸ºÐÇÕ´Ï´Ù. A±â´Â Á¡¸·¿¡ ±¹ÇÑµÈ ´ëÀå¾ÏÀÌ°í B±â´Â ´ëÀå¿¡ ±¹ÇÑµÈ ´ëÀå¾ÏÀÌ´Ù. ÀÌÁß¿¡¼­ B1±â´Â °íÀ¯±ÙÃþ±îÁö, B2±â´Â ´ëÀå¾ÏÀÌ À帷ÃþÀ» ¶Õ°í ³ª°£ »óÅÂÀÌ°í, B3±â´Â ´ëÀå¾ÏÀÌ ÀÎÁ¢ÇÑ Àå±â¿¡ À¯ÂøµÇ°Å³ª ħ½ÀÇÑ »óÅÂÀÌ´Ù. ±×¸®°í C±â´Â ±¹¼Ò ¸²ÇÁÀý±îÁö ÀüÀÌµÈ »óÅÂÀÌ°í, ÀÌÁß¿¡¼­ C1±â´Â B1ÇÔ²² ±¹¼Ò ¸²ÇÁÀý ÀüÀÌ, C2±â´Â C3±â´Â °¢°¢ B2, B3¿¡ ±¹¼Ò ¸²ÇÁÀý ÀüÀÌ°¡ ÀÖ´Â °æ¿ìÀÌ°í, D±â´Â ¿ø°ÝÀüÀÌ°¡ ÀÖ´Â °æ¿ì·Î Á¤ÀÇÇÑ´Ù. ¶Ç Çϳª´Â AJCC¿Í UICC¶ó´Â ±â°ü¿¡¼­ ¸ðµç Á¾·ùÀÇ ¾Ï¿¡ ´ëÇÑ º´±â¸¦ ¼³Á¤ÇÏ´Â ¹æ¹ýÀÌ ÀÖ¾î ÀÌ µÎ °¡Áö ¹æ¹ýÀÌ °í·ç ¾²ÀÔ´Ï´Ù. »ç½Ç µÎ º´±âÀÇ ³»¿ë¿¡´Â Å« Â÷ÀÌ°¡ ¾ø°í, ´ëÀå¾ÏÀÌ ´ëÀ庮À» ¾î´À Á¤µµ ħ½ÀÇÏ¿´´ÂÁö ¶Ç´Â ÀÎÁ¢ Àå±â±îÁö ħ½ÀÇÏ¿´´ÂÁö¸¦ ³ªÅ¸³»´Â TÀÎÀÚ, ¸²ÇÁÀý ÀüÀÌÀÇ Á¤µµ¸¦ Æò°¡ÇÑ NÀÎÀÚ, ¸Ö¸® ¶³¾îÁø Àå±â·ÎÀÇ ÀüÀÌ ¿©ºÎ¸¦ ³ªÅ¸³»´Â MÀÎÀÚ¸¦ Á¾ÇÕÇÏ¿© º´±â¸¦ ÆÇÁ¤ÇÑ´Ù. ±×·¯³ª ¼ö¼ú ÈÄ ÀýÁ¦ÇÑ Á¶Á÷À» Çö¹Ì°æÀ¸·Î °üÂûÇÏ¿© ¾îµð±îÁö ÁøÇàµÇ¾ú´ÂÁö È®ÀÎÇÔÀ¸·Î½á º´±â¸¦ Á¤È®ÇÏ°Ô ÆÇÁ¤ÇÒ ¼ö ÀÖ°í ÀÌ´Â Ãß°¡ Ä¡·áÀÇ Çʿ伺 ¶Ç´ÂÄ¡·á ¹æ¹ýÀ» °áÁ¤Çϰųª ¿¹Èĸ¦ ÃßÁ¤ÇÏ´Â µ¥ À־ °¡Àå Áß¿äÇÑ ÁöÇ¥°¡ µÈ´Ù.

      ÃÖ±Ù ³»½Ã°æ °Ë»çÀÇ Áõ°¡·Î Á¶±â ´ëÀå¾Ï¿¡ ´ëÇÑ ºóµµ¿Í °ü½ÉÀÌ ´Ã¾î³ª ÀÖ´Â »óÅÂÀÌ´Ù. Á¶±â ´ëÀå¾ÏÀ̶õ ´ëÀå¾ÏÀÌ Á¡¸·Ãþ ¶Ç´Â Á¡¸·ÇÏÃþ±îÁö¸¸ ħ½ÀÇÑ °æ¿ì¸¦ ¸»ÇÏ°í, ÀÌ ½Ã±â¿¡´Â ÀûÀýÈ÷ Ä¡·áÇÏ¸é °ÅÀÇ 100% ¿ÏÄ¡ÇÒ ¼ö ÀÖ´Ù. ÀÌ·± °æ¿ì´Â ´ë°³ ³»½Ã°æÀ» ÀÌ¿ëÇÑ ¿ëÁ¾ÀýÁ¦¼ú, Á¡¸·ÀýÁ¦¼ú / Á¡¸·ÇϹڸ®¼úÀÌ ½ÃÇàµÇ¸ç Á÷Àå¾ÏÀÎ °æ¿ì´Â °æÇ×¹®¹Ì¼¼¼ö¼úÀ̳ª °æÇ×¹®±¹¼ÒÀýÁ¦¼ú·Î °£´ÜÇÏ°Ô Ä¡·áÇÒ ¼ö ÀÖ´Ù.

6. Ä¡·á
    • ´ëºÎºÐÀÇ ´ëÀå¾ÏÀº ¼ö¼úÀû Á¦°Å°¡ ÀÏÂ÷ÀûÀÎ Ä¡·áÀÌ°í, ÃÖ±Ù ¼ö¼ú ÀüÈÄÀÇ Ç×¾ÏÁÖ»ç¿ä¹ý, ¹æ»ç¼±Ä¡·á¿ä¹ý ¹× ¸é¿ª¿ä¹ý¿¡ ´ëÇÑ ¿¬±¸°¡ È°¹ßÈ÷ ÁøÇàµÇ°í ÀÖ´Ù. Aº´±â³ª B1º´±â¿¡¼­´Â ¼ö¼ú ÈÄ¿¡ Ç×¾ÏÁֻ糪 ¹æ»ç¼±Ä¡·á°¡ ÇÊ¿äÇÏÁö ¾ÊÀ¸¸ç, Cº´±âÀÇ ´ëÀå¾Ï¿¡¼­´Â Ç×¾ÏÁֻ縦, Cº´±âÀÇ Á÷Àå¾Ï¿¡¼­´Â Ç×¾ÏÁÖ»ç¿Í ¹æ»ç¼±Ä¡·á¸¦ ÇÔ²² ½ÃÇàÇÏ´Â °ÍÀÌ Àç¹ß·üÀ» ³·Ãß°í 5³â »ýÁ¸À²À» Áõ°¡½ÃÅ°´Âµ¥ µµ¿òÀÌ µÈ´Ù. ´Ü, B2º´±â¿¡¼­´Â Ç×¾ÏÁÖ»ç¿Í ¹æ»ç¼±Ä¡·áÀÇ È¿°ú¿¡ ´ëÇؼ­ ÀÇ°ßÀÌ ÅëÀϵǾî ÀÖÁö ¾ÊÀº »óÅÂÀÌ´Ù. ´Ù¸¥ ¾Ï¿¡¼­´Â °£¿¡ ÀüÀ̵Ǿî ÀÖÀ¸¸é ¼ö¼úÀ» ÇÏÁö ¸øÇÏ´Â °ÍÀ¸·Î µÇ¾î ÀÖÀ¸³ª, ´ëÀå·Á÷Àå¾ÏÀÇ °æ¿ì¿¡´Â °£¿¡ ÀüÀ̵Ǿî ÀÖÀ» °æ¿ì¿¡µµ, ¿Ü°úÀûÀ¸·Î ±ÙÄ¡Àû ÀýÁ¦¸¦ ½ÃÇàÇϴµ¥, ±ÙÄ¡Àû ÀýÁ¦¸¦ Çϸé 25~30%ÀÇ 5³â »ýÁ¸À²À» ±â´ëÇÒ ¼ö ÀÖÀ¸³ª, ÀýÁ¦ÇÏÁö ¾ÊÀº °æ¿ìÀÇ 5³â »ýÁ¸À²Àº 5% ÀÌÇÏÀ̱⠶§¹®ÀÌ´Ù. ´Ü ´Ù¹ß¼º °£ÀüÀÌ¿¡ ´ëÇؼ­´Â ÀÌ·± Ä¡·á ¹æ¹ýÀ» Àû¿ëÇϱ⠾î·Æ´Ù.

      ÀýÁ¦°¡ ºÒ°¡´ÉÇÑ ÀüÀ̼º ´ëÀå¾Ï ȯÀÚ¿¡¼­´Â ´ë»ó ¼±Á¤¿¡ À¯ÀÇÇÏ¿©¾ß ÇÑ´Ù, Ãֱ٠ǥÀûÄ¡·áÁ¦ÀÇ °³¹ß°ú ¿¹ÃøÀÎÀÚ È®¸³¿¡ ÀÇÇÏ¿© Ç×¾ÏÈ­Çпä¹ýÀÌ ¹ßÀüÇÏ°Ô µÇ¾ú´Ù. ÀÌ·Î ÀÎÇÏ¿© ¼ö¼úÀÌ °¡´ÉÇÑ ÀüÀ̼º º´º¯À¸·Î ÀüȯµÇ´Â °æ¿ì°¡ ¸¹¾ÆÁ³´Ù. µû¶ó¼­ Àû±ØÀûÀÎ Ä¡·á ¹æħÀ» ¼³Á¤ÇÏ´Â °ÍÀÌ Áß¿äÇÏ´Ù.

7. ¿¹ÈÄ
    • ´ëÀå·Á÷Àå¾ÏÀ» ¼ö¼úÇÑ ÈÄ¿¡´Â ¶¼¾î³½ Á¶Á÷À» Á¤¹Ð °Ë»çÇÏ¿© º´±â¸¦ ÆÇÁ¤Çϸç, º´±â¿¡ µû¶ó ¿¹ÈÄ°¡´Ù¸£´Ù. ´ëÀå¾ÏÀº ´Ù¸¥ ¼ÒÈ­±â ¾Ï¿¡ ºñÇØ ¿¹ÈÄ°¡ ÁÁÀº ÆíÀ¸·Î 5³â »ýÁ¸À²ÀÌ Aº´±â¿¡¼­´Â 90%, Bº´±â¿¡¼­´Â 75%, Cº´±â¿¡¼­´Â 50%À̸ç, Dº´±â´Â 1~2% Á¤µµÀÌ´Ù. ¸¸¾à ´ëÀå·Á÷Àå¾ÏÀÌ Á¶±â¿¡ ¹ß°ßµÇ¾î ¼ö¼ú·Î ¿ÏÀüÈ÷ ¶¼¾î³»¾ú´Ù ÇÏ´õ¶óµµ ¾ÏÀÌ ÁøÇàµÇ¾ú´Ù¸é »ýÁ¸·üÀº 50% ÀÌÇÏ·Î ¶³¾îÁö°Ô µÈ´Ù.

    Âü°í¹®Çå

    1. Korea Central Cancer Resistry. Annual report of the Korea Central Cancer Registry 2009. Goyang: National Cancer Center; 2011.

    2. Stewart BW, Kleihues P. World cancer report. Lyon: IARCPress;2003. p. 198.

    3. Armstrong B, Doll R. Evironmental factors and cancer incidence and mortality in different countries, with special reference to dietary practices. Int J Cancer 1975;15:617-31.

    4. Willett WC, Stampfer MJ, Colditz GA, Rosner BA, Speizer FE. Relation of meat, fat, and fiber intake to the risk of colon cancer in a prospective study among women. N Engl J Med 1990;323:1664-72.

    5. Agrawal J, Syngal S. Colon cancer screening strategies. Curr Opin Gastroenterol 2005;21:59-63.

    6. Mandel JS, Bond JH, Church TR, et al. Reducing mortality from colorectal cancer by screening for fecal occult blood.Minnesota Colon Cancer Control study. N Engl J Med 1993;328:1365-1371.

    7. Hardcastle JD, Chamberlain JO, Robinson MH, et al. Randomized controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 1996;348:1472-1477.

    8. Mandel JS, Church TR, Ederer F, Bond JH. Colorectal cancermortality: effectiveness of biennial screening for fecal occult blood. J Natl Cancer Inst 1999;91:434-437.

    9. Nadel MR, Shapiro JA, Klabunde CN, Seeff LC, Uhler R, Smith RA, Ransohoff DF. A national survey of primary care physicians' methods for screening for fecal occult blood. Ann Intern Med 2005;142:86-94.

    10. Ahlquist DA, McGill DB, Schwartz S, Taylor WF, Owen RA. Fecal blood levels in health and disease. A study using HemoQuant. N Engl J Med 1985;312:1422-1428.

    11. Rex DK, Johnson DA, Lieberman DA, Burt RW, Sonnenberg A. Colorectal cancer prevention 2000: screening recommendations of the American College of Gastroenterology. Am J Gastroenterol 2000;95:868-877.

    12. Screening for colorectal cancer. In: Preventive Services Task Force. Guide to clinical preventive services. 2nd ed. Baltimore: Williams & Wilkins, 1996;89-103.

    13. Winawer SJ, Fletcher RH, Miller L, et al. Colorectal cancer screening: clinical guidelines and rationale. Gastroenterology 1997;112:594-642.

    14. Imperiale TF, Wagner DR, Lin CY, Larkin GN, Rogge JD, Ransohoff DF. Risk of advanced proximal neoplasms in asymptomatic adults according to the distal colorectal findings. N Engl J Med 2000;343:169-174.

    15. Lieberman DA, Weiss DG, Bond JH, Ahnen DJ, Garewal H, Chejfec G. Use of colonoscopy to screen asymptomatic adults for colorectal cancer. Veterans Affairs Cooperative Study Group 380. N Engl J Med 2000;343:162-168.

    16. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003;21:60-65.

    17. Kabbinavar FF, Schulz J, McCleod M, et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastaticcolorectal cancer: results of a randomized phase II trial. J Clin Oncol 2005;23:3697-3705.

    18. Chung HH, Jang BI. A prospective: role of targeted therapy in colon cancer. Korean J Gastroenterol 2013;61:128-135.